


Figure S4



No. at Risk							
Rivoceranib	80	62	45	28	15	8	5
VEGFRI-naïve	66	51	37	25	13	8	5
VEGFRI-treated	14	11	8	3	2	0	0

**Figure S4. Kaplan-Meier estimate of progression-free survival by blinded independent review committee in the intention-to-treat population.** Progression-free survival assessed by blinded independent review committee by prior VEGFR inhibitor treatment.